Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies.

CONCLUSIONS:  Oncolytic Ad5NULL-A20 virotherapies represent an excellent vector for local and systemic targeting of αvβ6-over-expressing cancers, and exciting platforms for tumour selective over-expression of therapeutic anti-cancer modalities, including immune checkpoint inhibitors.
PMID: 29798908 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 24, 2018 Category: Cancer & Oncology Authors: Uusi-Kerttula H, Davies JA, Thompson J, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile R, Chester JD, Parker AL Tags: Clin Cancer Res Source Type: research